This website uses cookies to enhance the user experience.
PLUVIA AS

PLUVIA AS916 635 559

Research
Limited company
Thormøhlens gate 51 5006 BERGEN, Norge

PLUVIA AS

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Links

Organization

CEO
Chairman of the board
Years since formation
8 years
since Feb 11, 2016
Type
Limited company
VAT registered
Yes
Number of employees
5

Ownership

Number of shares and share classes
133,586
1 share class
Total number of shareholders
10
4 companies, 6 persons

Financials

Annual total result 2023
-7,496,442
NOK
Total equity 2023
7,588,724
NOK
Last update: Aug 29, 2024

Management

Management / administration

NameRoleShares
Managing Director/CEO-

Board

NameRoleShares
Board Member
4.01 %
directly
Board Member-
Board Member-
Chairman-
Board Member-
Alternate Member-
Board Member-

Others

NameRoleShares
R
RSM NORGE AS
Auditor-
E
ECIT SERVICES AS
Accountant-

Top 10 individual shareholders

NameRoleShares
Board Member
4.01 %
directly
-
3.28 %
indirectly
-
2.29 %
directly
-
1.72 %
directly
-
1.72 %
directly
Last update: Apr 11, 2024

Ownership

Company shareholders

NameShare classNumber of sharesShare
S
SARSIA SEED FOND II AS
Ordinary shares
40,903
30.62 %
Ordinary shares
38,645
28.93 %
Ordinary shares
21,520
16.11 %
I
INVESTINOR DIREKTE AS
Ordinary shares
17,218
12.89 %
Ordinary shares
5,355
4.01 %
Ordinary shares
3,060
2.29 %
Ordinary shares
2,295
1.72 %
Ordinary shares
2,295
1.72 %
MY
Ordinary shares
1,148
0.86 %
Ordinary shares
1,147
0.86 %
Last update: May 24, 2024

Financials

in NOK

Summary

Year202320222021
Total operating income
0
0
0
Annual Total Result
-7,496,442
-4,114,918
-4,703,191
Total assets
9,095,965
9,005,117
14,029,215
Total liabilities
1,507,241
2,919,861
3,829,041
Total equity
7,588,724
6,085,256
10,200,174

P&L

Year202320222021
Total operating income
0
0
0
Total operating costs
7,502,464
4,075,385
4,724,668
Operating result
-7,502,464
-4,075,385
-4,724,668
Financial income/costs
6,023
-39,534
21,477
Profit before tax
-7,496,442
-4,114,918
-4,703,191
Total tax & extraordinary income/cost
0
0
0
Annual Total Result
-7,496,442
-4,114,918
-4,703,191

Balance overview

Year202320222021
Total fixed assets
60,000
60,000
60,000
Total current assets
9,035,965
8,945,117
13,969,215
Total assets
9,095,965
9,005,117
14,029,215
Short term debt
1,507,241
2,919,861
3,829,041
Long term debt
0
0
0
Total liabilities
1,507,241
2,919,861
3,829,041
Contributed capital
7,588,724
6,085,256
10,200,174
Retained earnings
0
0
0
Total equity
7,588,724
6,085,256
10,200,174
Total equity and liabilities
9,095,965
9,005,117
14,029,215

Classification

Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
M
Main industrial area
Professional, scientific and technical activities
72
Activity
Scientific research and development
72.1
Main industrial group
Research and experimental development on natural sciences and engineering
72.11
Industrial group
Research and experimental development on biotechnology
72.110
Industrial group
Research and experimental development on biotechnology